Prolia (Denosumab) vs Evenity (Romosozumab): Side-Effect Profile Head-to-Head

How Each Drug Works and Why Side Effects Differ

Prolia (denosumab) is a monoclonal antibody that binds RANK ligand, suppressing osteoclast formation and bone resorption. Evenity (romosozumab) inhibits sclerostin, a protein that restrains osteoblast activity, producing a dual effect: it builds new bone while simultaneously reducing resorption. These distinct mechanisms explain why the two drugs produce different safety signals.

Prolia's Antiresorptive Mechanism

Because denosumab suppresses the entire osteoclast lineage, its effect is fully reversible once the drug clears. That reversibility is both an advantage (predictable offset) and a liability (rebound bone loss). The FREEDOM trial (N=7,808) demonstrated a 68% reduction in vertebral fractures over 36 months with denosumab versus placebo 1. Adverse events in FREEDOM included eczema (3.0% vs 1.7%), flatulence (2.2% vs 1.4%), and cellulitis (0.3% vs <0.1%) [1].

Evenity's Bone-Building Mechanism

Romosozumab's anabolic action produces rapid bone mineral density (BMD) gains. In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months 2. The sclerostin pathway, however, intersects with vascular biology, which likely underlies the cardiovascular signal detected in ARCH [2].

No Direct Head-to-Head Safety Trial Exists

No published randomized trial compares the side-effect profiles of denosumab and romosozumab directly. The FRAME trial (romosozumab vs placebo) and the FREEDOM trial (denosumab vs placebo) used different comparators, endpoints, and patient populations. All safety comparisons are therefore cross-trial, and readers should interpret them with that limitation in mind.

Cardiovascular Risk: Evenity's Black-Box Warning

Evenity is the only osteoporosis biologic with a black-box cardiovascular warning from the FDA. The concern arose from the ARCH trial, where adjudicated serious cardiovascular events occurred in 2.5% of romosozumab-treated patients versus 1.9% of alendronate-treated patients over the first 12 months of therapy 2.

The ARCH Cardiovascular Signal

Fifty patients in the romosozumab group experienced a major adverse cardiovascular event (MACE) during the first year, compared with 38 in the alendronate group. The absolute risk difference was small (0.6 percentage points), and the hazard ratio confidence interval was wide, but the FDA deemed the signal sufficient for a boxed warning.

Who Should Avoid Evenity

The prescribing information contraindicates Evenity in patients who have had a myocardial infarction or stroke within the preceding year. The 2020 American Association of Clinical Endocrinology (AACE) guidelines recommend that clinicians weigh fracture risk against cardiovascular risk before initiating romosozumab, particularly in patients over age 70 with established atherosclerotic disease.

Prolia's Cardiovascular Profile

Denosumab showed no cardiovascular safety signal in FREEDOM or its long-term extension (up to 10 years). A post-hoc analysis of FREEDOM found no increase in MACE with denosumab versus placebo 1. For patients with high cardiovascular risk who need potent osteoporosis therapy, denosumab is typically the safer choice on this axis.

Rebound Vertebral Fractures: Prolia's Defining Risk

Denosumab's most consequential safety concern is the rapid bone loss and clustering of vertebral fractures that can occur after discontinuation. This rebound phenomenon has no parallel with romosozumab.

Mechanism of Rebound

When denosumab clears (roughly 6 months after the last injection), osteoclast activity surges above pre-treatment levels. Bone turnover markers such as CTX can overshoot baseline by 2- to 3-fold. A 2017 case series published in the Journal of Bone and Mineral Research documented multiple vertebral fractures within 7 to 16 months of denosumab cessation 3.

Clinical Scale of the Problem

A systematic review by Tsourdi et al. (2017) found that the incidence of multiple vertebral fractures after stopping denosumab ranged from 5% to 10% depending on baseline risk factors 3. The Endocrine Society's 2020 position statement recommended that patients transitioning off denosumab receive a bisphosphonate (typically zoledronic acid or alendronate) to prevent rebound.

Why Evenity Does Not Cause Rebound

Romosozumab's bone-forming effect tapers naturally after 12 months as the sclerostin pathway adapts. There is no documented overshoot of osteoclast activity post-romosozumab. BMD may plateau or slowly decline after the 12-dose course, but the pattern differs fundamentally from the abrupt resorptive surge seen with denosumab withdrawal. Patients still need follow-on antiresorptive therapy (usually denosumab or a bisphosphonate) to maintain gains.

Injection-Site Reactions and Common Adverse Events

Both drugs are administered subcutaneously, so injection-site reactions are common to both. The frequency and pattern, however, differ.

Prolia Injection-Site Profile

In FREEDOM, injection-site reactions with denosumab (60 mg every 6 months) were infrequent and generally mild. Fewer than 1% of patients reported significant local reactions. Because Prolia involves only two injections per year, cumulative exposure at the injection site is low 1.

Evenity Injection-Site Profile

Romosozumab requires two subcutaneous injections at each monthly visit (each syringe delivers 105 mg for a total dose of 210 mg). Injection-site reactions were reported in 5.2% of romosozumab patients in the FRAME trial versus 2.9% for placebo 4. Pain, erythema, and swelling were the most common local complaints. Over 12 monthly visits (24 total injections), patients receive substantially more needle exposures than with Prolia.

Other Frequent Adverse Events Compared

The table below summarizes the most commonly reported adverse events from each drug's key trial. Rates are not directly comparable because trial designs, populations, and comparators differed.

| Adverse event | Prolia (FREEDOM) | Evenity (ARCH / FRAME) | |---|---|---| | Arthralgia | 11.3% | 12.4% | | Back pain | 11.5% | 8.7% | | Nasopharyngitis | 6.7% | 13.6% | | Headache | 4.0% | 5.2% | | Injection-site reaction | <1% | 5.2% | | Hypocalcemia (symptomatic) | Rare | Rare |

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, noted in a 2018 review: "The everyday tolerability of both agents is good. It is the rare but serious events, and the consequences of stopping therapy, that should drive the choice between them" 5.

Rare but Serious: ONJ and Atypical Femoral Fractures

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are class-effect concerns for all potent antiresorptive agents. Both have been reported with Prolia. The signal with Evenity is far less established due to its shorter time on market and its 12-month treatment cap.

ONJ with Prolia

In the FREEDOM extension study (up to 10 years of denosumab), the incidence of ONJ was 5.2 per 10,000 patient-years 6. Risk factors include invasive dental procedures, poor oral hygiene, and concurrent corticosteroid use. The American Dental Association's 2022 guidance recommends a dental examination before initiating denosumab.

AFF with Prolia

Atypical femoral fractures were reported in 2 patients during the FREEDOM extension (out of 4,550 patients followed for up to 10 years). The rate is lower than that seen with long-term bisphosphonate therapy, but the cumulative risk may increase with extended denosumab use beyond 5 to 10 years 6.

ONJ and AFF with Evenity

Romosozumab is typically administered for only 12 months, which limits cumulative antiresorptive exposure. In the ARCH and FRAME trials, ONJ occurred in 1 romosozumab-treated patient (out of over 4,000) and no AFF events were reported 2. Post-marketing surveillance has not changed this picture substantially.

Hypocalcemia and Metabolic Monitoring

Both drugs can lower serum calcium, though the clinical significance varies.

Denosumab and Calcium

Denosumab suppresses bone resorption rapidly, which can cause hypocalcemia within days of the first injection, particularly in patients with pre-existing vitamin D deficiency or chronic kidney disease (CKD stage 4-5). The FDA label requires adequate calcium and vitamin D supplementation before each dose, and recommends monitoring serum calcium within 14 days of injection in patients at risk.

Romosozumab and Calcium

Romosozumab can also cause mild hypocalcemia, but severe cases are less common in trials. The FRAME trial reported hypocalcemia in 0.4% of romosozumab patients versus 0.2% of placebo patients 4. As with denosumab, the prescribing information mandates correction of hypocalcemia and vitamin D deficiency before starting therapy.

Duration of Therapy and Long-Term Safety Implications

The treatment duration for each drug shapes its cumulative safety profile in a way that single-timepoint comparisons miss.

Prolia: Open-Ended Therapy

Prolia has no predefined stopping point. The FREEDOM extension followed patients for 10 years on continuous denosumab. BMD continued to increase throughout, and fracture rates remained low 6. The trade-off: the longer a patient remains on denosumab, the more dependent their skeleton becomes on continued dosing, and the higher the stakes of discontinuation. Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research and Osteoporosis Center, stated: "Denosumab is easy to start but hard to stop. Every prescriber should have an exit strategy before writing the first prescription" 7.

Evenity: Built-In Stopping Point

Evenity's 12-month course eliminates the question of indefinite therapy. After 12 doses, patients transition to an antiresorptive agent. The cardiovascular risk is therefore confined to a finite window. Long-term safety data beyond the initial 12 months of romosozumab exposure are limited, since the drug is not intended for repeated courses (though off-label re-treatment is being studied).

Transition Strategies

Both drugs require a clear follow-on plan. After Prolia, a bisphosphonate must be initiated within 6 months of the last dose to prevent rebound. After Evenity, patients typically start denosumab or alendronate to lock in BMD gains. The 2020 Endocrine Society guideline provides sequencing algorithms for both scenarios [8].

Which Patients Suit Which Drug Based on Safety

There is no universally "safer" drug. The better choice depends on the individual patient's risk profile.

Choose Prolia When

The patient has high cardiovascular risk (prior MI, prior stroke, established peripheral artery disease) or is over 70 with multiple atherosclerotic risk factors. Prolia's absence of a cardiovascular signal makes it the default in this population. The patient must, however, be counseled on the need for long-term adherence or a carefully planned transition to a bisphosphonate.

Choose Evenity When

The patient has very high fracture risk (prior vertebral fracture, T-score below -3.0, or high FRAX probability) and low cardiovascular risk. Romosozumab's anabolic mechanism produces faster and larger BMD gains than denosumab during its 12-month course. The time-limited exposure also simplifies the exit strategy. The AACE/ACE 2020 algorithm classifies romosozumab as a first-line option for "very high fracture risk" patients who can tolerate the cardiovascular profile 9.

When Both Are Reasonable

In patients with moderate fracture risk and no significant cardiovascular history, both drugs are defensible choices. Practical factors then dominate: Prolia's twice-yearly dosing is more convenient than Evenity's monthly visits, but Evenity's finite course avoids the indefinite-therapy commitment and rebound concern.

Immunogenicity and Hypersensitivity

Denosumab has low immunogenicity. Anti-drug antibodies were detected in fewer than 1% of patients in FREEDOM, and none were neutralizing 1. Rare cases of anaphylaxis, dermatitis, and rash have been reported post-marketing.

Romosozumab generated anti-drug antibodies in approximately 18% of patients in the FRAME trial, with neutralizing antibodies in 0.7% 4. The presence of antibodies did not appear to reduce efficacy or increase adverse events in the trial population, but the higher immunogenicity rate is a point of monitoring interest.

Putting the Numbers Together

Neither Prolia nor Evenity is the categorically safer drug. Prolia's side-effect burden is dominated by the rebound fracture risk upon stopping and a small cumulative risk of ONJ with long-term use. Evenity's burden centers on the cardiovascular signal during its 12-month treatment window. The 2024 ASBMR position paper recommends individualized risk-benefit discussion incorporating FRAX score, 10-year MACE risk, and patient preference for treatment duration before selecting either agent 10.

Baseline serum 25-hydroxyvitamin D should be above 30 ng/mL and serum calcium within the normal range before initiating either drug.